Kenneth T. Mills - Jul 16, 2024 Form 4 Insider Report for REGENXBIO Inc. (RGNX)

Role
Director
Signature
/s/ Patrick J. Christmas as attorney-in-fact
Stock symbol
RGNX
Transactions as of
Jul 16, 2024
Transactions value $
-$24,130
Form type
4
Date filed
7/18/2024, 05:05 PM
Previous filing
May 16, 2024
Next filing
Jul 26, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RGNX Common Stock Options Exercise $752 +200 +0.05% $3.76 408K Jul 16, 2024 Direct F1
transaction RGNX Common Stock Sale -$2.75K -200 -0.05% $13.76 408K Jul 16, 2024 Direct F1
transaction RGNX Common Stock Options Exercise $8.31K +2.21K +0.54% $3.76 410K Jul 17, 2024 Direct F1
transaction RGNX Common Stock Sale -$30.4K -2.21K -0.54% $13.77 408K Jul 17, 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RGNX Stock Options (Right to Buy) Options Exercise $0 -200 -0.25% $0.00 81.2K Jul 16, 2024 Common Stock 200 $3.76 Direct F1, F3
transaction RGNX Stock Options (Right to Buy) Options Exercise $0 -2.21K -2.72% $0.00 78.9K Jul 17, 2024 Common Stock 2.21K $3.76 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 trading plan.
F2 This transaction was executed in multiple trades at prices ranging from $13.76 to $13.80. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3 The previously granted option, representing a right to purchase a total of 275,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on May 19, 2016, and the balance vested in equal monthly installments over the 36 months thereafter.